Efficacy

Imfinzi (Durvalumab) Efficacy in Lung Cancer

Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody used in the treatment of lung cancer. Specifically, it has shown efficacy in the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors cannot be surgically removed and whose cancer has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Clinical trials have demonstrated that durvalumab significantly improves median progression-free survival compared to placebo, offering a new hope for patients with this type of lung cancer.

The PACIFIC trial, a pivotal phase III study, has provided evidence for the efficacy of durvalumab in this setting. In this trial, durvalumab treatment resulted in a significant improvement in overall survival compared to placebo. The results indicated that the risk of death was reduced by approximately 32%, which is a substantial advancement in the treatment of stage III NSCLC. These findings have established durvalumab as a standard of care for patients with unresectable stage III NSCLC following chemoradiotherapy.

Rybrevant (Amivantamab-vmjw) Efficacy in Lung Cancer

Rybrevant (amivantamab-vmjw) is a bispecific antibody that targets epidermal growth factor receptor (EGFR) and MET receptor pathways, which are often implicated in the pathogenesis of NSCLC. It has been approved for the treatment of adult patients with NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This approval was based on the results of the CHRYSALIS trial, a multicenter, open-label, multicohort study.

In the CHRYSALIS trial, amivantamab-vmjw demonstrated a clinically meaningful response rate in patients with NSCLC harboring EGFR exon 20 insertion mutations. The overall response rate reported from the trial was notable, suggesting that amivantamab-vmjw can provide a significant benefit to this patient population, who previously had limited treatment options. Additionally, the duration of response observed in the study indicates that amivantamab-vmjw can offer sustained disease control for patients with this specific genetic alteration in NSCLC.